Researchers from Geneseeq and a network of Chinese academic hospitals have validated a blood test that can detect a broad range of cancers with high accuracy using cell-free DNA. A multi-cancer early ...
Researchers combined protein biomarkers, cfDNA analysis, and machine learning to open opportunities for early-stage ovarian cancer screening and diagnostics. The cfDNA fragmentome is a genome-wide ...
We conducted a systematic meta-analysis of 30 studies involving 3,287 patients with postoperative NSCLC to evaluate the diagnostic performance of ctDNA-based MRD testing for recurrence detection and ...
Cancer is one of the leading causes of death globally, with nearly 20 million new cases and 9.7 million deaths in 2022. Early detection plays a crucial role in reducing cancer-related morbidity and ...
The discovery began, as many breakthroughs do, with an observation that didn’t quite make sense. In 1948, two French researchers, Paul Mandel and Pierre Métais, published a little-noticed paper in a ...
Dear Dr. Roach: I am 85 and healthy apart from polycythemia vera, for which I take aspirin. I was interested in the new blood test for cancer. Is it worthwhile? — M.N. Answer: When screening patients ...
Elegen and Nutcracker Therapeutics launched a pilot program to demonstrate what they label the industry’s first fully synthetic, cell-free manufacturing platform for RNA-based personalized cancer ...
Elegen, a global leader in next-generation DNA manufacturing, and Nutcracker Therapeutics, a global leader in next-generation RNA design and manufacturing, today announced the launch of a pilot ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results